Trials / Completed
CompletedNCT01461590
Study of Safe Blood Transfusion Volumes to Correct Acute Severe Anaemia
Phase II Trial of Transfusion Volumes in Children With Acute Severe Anaemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (actual)
- Sponsor
- Prof Kathryn Maitland · Academic / Other
- Sex
- All
- Age
- 60 Days – 12 Years
- Healthy volunteers
- Not accepted
Summary
Greater volume of whole blood(30mls/kg compared to 20mls/kg) following standard calculations, given to children with severe anaemia will be beneficial in haematological correction and can be given safely since respiratory distress and haemodynamic changes result from acidosis and compensation in these children rather than from biventricular failure.
Detailed description
Severe anemia (SA, hemoglobin \<6 g/dl) is a leading cause of pediatric hospital admission in Africa, with significant in-hospital mortality. The underlying etiology is often infectious, but specific pathogens are rarely identified. Guidelines developed to encourage rational blood use recommend a standard volume of whole blood (20 ml/kg) for transfusion, but this is commonly associated with a frequent need for repeat transfusion and poor outcome. Evidence is lacking on what haemoglobin threshold criteria for intervention and volume are associated with the optimal survival outcomes. We evaluated the safety and efficacy of a higher volume of whole blood (30 ml/kg; Tx30: n = 78) against the standard volume (20 ml/kg; Tx20: n = 82) in Ugandan children (median age 35.5 months (interquartile range (IQR) 12.5 to 52.5)) for 24-hour anemia correction (hemoglobin \>6 g/dl: primary outcome) and 28-day survival.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Whole blood | 30mls/kg transfused over fours hours |
| OTHER | Whole blood | 20mls/kg transfused over four hours |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2012-01-01
- Completion
- 2012-01-01
- First posted
- 2011-10-28
- Last updated
- 2015-04-01
Locations
2 sites across 1 country: Uganda
Source: ClinicalTrials.gov record NCT01461590. Inclusion in this directory is not an endorsement.